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A B S T R A C T
Outcome for elderly patients with acute myeloid leukemia (AML) is extremely poor. Intensive induction che-
motherapy is often unsuitable. Sixty-six newly diagnosed AML patients (median age: 76 years), ineligible for
standard therapy, were consecutively treated with low-dose lenalidomide (10 mg/day orally, days 1–21) plus
10 mg/m2 low-dose cytarabine, subcutaneously, twice a day (days 1–15) every six weeks, up to 6 cycles.
Complete remission (CR) rate was 36.3% according to intention-to-treat. Responding patients had a longer
median overall survival than non-responders (517 vs. 70 days, P < 0.001). The achievement of CR was not
predicted by bone marrow blast count, cytogenetics, molecular markers, prior MDS, white blood cell count.
Conversely, by studying the global gene expression profile, we identified a molecular signature, including 309
genes associated with clinical response (CR versus no CR). Based on the expression of a minimal set of 16 genes,
we developed an algorithm to predict treatment response, that was successfully validated by showing an overall
accuracy of 88%. We met the primary endpoint of the study, by beating the estimated successful CR rate (P1)
fixed at 30%. Moreover, CR induced by this 2-drug combo was efficiently predicted by genetic profiling,
identifying a biomarker that warrants validation in independent series.
1. Introduction
The incidence of acute myeloid leukemia (AML) increases with age,
and outcome for elderly patients remains extremely poor [1]. These
patients have a poor prognosis, with median overall survival rates of
less than 1 year, and further duration of survival in patients aged se-
venty or more [2,3]. Intensive induction chemotherapy is often un-
suitable for elderly patients and can result in significant periods of in-
patient care [3,4]. Furthermore, no currently available treatment
option for older patients with AML has shown any significant survival
advantage compared to any other. Thus, novel therapeutic agents are
urgently needed for older AML patients, in particular drugs with re-
duced toxicity and a specific mechanism of action, if compared to
standard chemotherapy [5]. In this regard, a major goal when testing
new drugs or combinations is to identify reliable biomarkers able to
predict which patients are more likely to achieve clinical response [6].
Cytosine arabinoside is a mainstay in the treatment of acute myeloid
leukemia. The cytotoxic effect depends on the conversion to its tri-
phosphate form in leukemic cells, which is close related to the balance
between phosphorylating and dephosphorylating enzymes [7]. In ad-
dition, the sensitivity to cytarabine-triphosphate-induced citotoxicity is
dependent on the balance between pro and antiapoptotic signals in the
leukemic cell [7].
Lenalidomide has shown to be effective in del(5q)-associated mye-
lodisplasia (MDS) or AML [8,9], and in AML without del(5q) when
administered at high doses [10,11]. A recent phase I–II study demon-
strated the activity of lenalidomide in combination with azacitidine in
AML patients older than 60 years [12,13]. However, up to now, no
report identified reliable biomarkers able to predict which AML patients
are more likely to respond to lenalidomide, either when administered
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alone at high-doses, or when combined with other drugs. Given these
premises, the preliminary results of this trial, already reported else-
where, showed the opportunity of predicting CR by studying the gene
expression profile of AML blasts at diagnosis [14]. However, con-
sidering the small sample size of the first stage of our trial, those results
needed to be confirmed in the entire patient population, as clearly
stated in the manuscript [14].
Here we report the final results of a phase II study conducted on 66
elderly AML patients, aged seventy years or more, not eligible for
standard chemotherapy, without deletion 5q, treated with low-dose
lenalidomide coupled with low-dose cytarabine. Furthermore, based on
the hypothesis that the genetic features might influence treatment re-
sponse, we aimed at confirming the capability of predicting CR of the
previously identified gene dataset [14] by studying the global gene
expression profiles.
2. Materials &methods
2.1. Study design and patients
We did a prospective, multicentre, single arm study of a low-dose
chemotherapy regimen combining lenalidomide and cytarabine in very
elderly AML. Patients 70 years of age or older with a World Health
Organization diagnosis of AML (de novo, treatment-related, or trans-
formed MDS) were eligible for this study. Inclusion criteria were: pre-
viously untreated disease; no evidence of acute promyelocytic leu-
kemia; no eligibility for standard chemotherapy; WHO performance
status ≤2; white blood cells (WBC) ≤50.000/mm3 at the time of en-
rolment; normal hepatic function, defined as total bilirubin con-
centration less than 2.5 times the maximum normal concentration
(MNC) with AST and ALT concentration less than 3.5 times the MNC;
normal renal function, defined as creatinine concentration less than 1.5
the MNC, unless leukemia-related, and negative HIV serology test be-
fore enrolment. Exclusion criteria were: any prior chemotherapy for
AML; concurrent therapy for another malignancy; at least 6 months
since prior chemotherapy or radiotherapy for another malignancy;
patients with uncontrolled insulin-dependent diabetes mellitus or un-
compensated major thyroid or adrenal dysfunction; eligibility to receive
standard chemotherapy for AML.
Patients signed written informed consent before enrolment. The
study was approved by an independent research Ethics Committee and
was done in accordance with the International Conference on
Harmonisation Good Clinical Practice Guidelines, the Declaration of
Helsinki (1996), and local regulatory requirements and laws.
The first stage of this study, with data available on 33 patients, was
previously reported elsewhere. [14]
The study was registered at EMA with EUDRA-CT code number
2008-006790-33.
2.2. Procedures
Patients were treated with low-dose lenalidomide (10 mg) ad-
ministered orally once daily (days 1–21) and low-dose cytarabine
(10 mg/m2) administered subcutaneously twice daily (days 1–15).
Chemotherapy courses were repeated every 6 weeks in the absence of
disease progression or unacceptable toxicity, up to 6 cycles, without the
evidence of progressive disease. Bone marrow evaluation was per-
formed after 1, 2, 4 and 6 cycles of chemotherapy. In responding pa-
tients who experienced a non-hematological toxicity> 2 according to
WHO criteria, both drugs were administered at the same dosages but for
a shorter period of time: lenalidomide (10 mg, orally) once daily (days
1–14) cytarabine (10 mg, subcutaneously) twice daily (days 1–10).
Treatment was intended to be administered in an outpatients basis.
However, all patients required hospitalization for the first cycle of
therapy. Standard antimicrobial prophylaxis and supportive care mea-
sures were as reported elsewhere [15].
Toxicities were scored using the NCI’s Common Terminology
Criteria for Adverse Events, version 3 [16]. A serious AE was an AE that
resulted in death or immediate risk of death, prolonged hospitalization
or substantial disability. Responses were assessed according to the
LeukemiaNet guidelines [17]. Patients who completed one full cycle of
treatment were considered evaluable. Cytogenetic risk was assessed by
SWOG criteria [18].
Gene expression profile procedures, previously described elsewhere
[19,20], are reported in details in the supplementary material section.
2.3. Statistical analysis
With a one-arm sample size, we calculated the sample size on the
basis of a comparison to a fixed reference level. The study was designed
according to the MiniMax design. The primary outcome was the com-
plete remission rate. Fixing the lowest acceptable rate (P0) as 17% and
the successful rate (P1) as 30%, with a significance level α = 0.05 and a
power 1-β = 0.90, the sample size was estimated to be 66 patients, 33
during the first phase and 33 during the second phase. If 5 or fewer
responses were observed during the first stage, the trial would have
been stopped; if 16 of fewer responses are observed by the end of the
trial, then no further investigations should be warranted, and the
treatment rejected.
Statistical analysis was performed according to the intention to treat
approach. The primary efficacy analysis was performed using all pa-
tients who received at least one cycle of oral lenalidomide and sub-
cutaneous cytarabine. For further details, see supplementary materials.
2.4. Role of the funding source
This was an investigator-driven study. Celgene provided lenalido-
mide free of charge, without having any role in study design, data
collection, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
3. Results
3.1. Clinical results
Fig. 1 shows the trial profile. Sixty-six AML patients with a median
age of 76 years were consecutively enrolled in the study. The char-
acteristics of patients are listed in Table 1.
All the most relevant toxicities are reported in Table 2. Briefly, 8/66
patients (12%) died in documented aplasia after having received the
first cycle of therapy, due to infectious complications. One additional
death occurred also during cycle 1, after 8 days of combined therapy,
due to acute heart failure. Overall, CR rate was 36.3% (24/66 patients),
and PR rate 3% (2/66) according to intention-to-treat. According to the
study design, we met the primary endpoint of the study by achieving a
36.3% CR rate, better than the 30% fixed as the successful rate (P1).
Five out of 26 responding patients (19%) are still in CR after a median
follow-up time of 693 days (388–2092). Six patients died while in CR/
PR without completing the 6-cicles program (1 lung cancer, 4 due to a
multi-organ failure while receiving treatment, 1 unknown). Fifteen out
of 26 responding patients relapsed after a median time of 330 days
(range: 111–1559). At present, 11/15 relapsing patients died of leu-
kemia, whereas 4/15 are still alive with active disease. The achieve-
ment of CR was not predicted by any clinical or biological prognostic
factor widely used, such as bone marrow blasts, cytogenetics, molecular
markers, prior MDS, white blood cell at diagnosis.
Fig. 2 shows cumulative DFS, cumulative OS and OS according to
response. As expected, responding patients had a longer OS with respect
to patient who did not respond. Nevertheless, the median OS for pa-
tients achieving a CR was 517 days [95% CI 415–1085], significantly
higher (p = 0.01) with respect to patients who did not achieve a CR (70
G. Visani et al. Leukemia Research 62 (2017) 77–83
78
[95% CI 38–82] days).
3.2. Molecular profiling discriminated patients according to clinical
response
Based on the clinical results and, specifically, on the remarkable CR
rate, we next tried to identify a potential biomarker predictive of
treatment response. As no cytogenetic or known molecular abnormality
(including FLT3, NMP1, or CEBPA mutations) showed any significant
correlation with therapy response, we decided to study the global gene
expression profile (GEP). We analysed 26 patients for whom peripheral
blood or marrow AML cells collected at diagnosis were still available
and for whom a clear-cut clinical outcome (i. e. CR vs. no-CR) could be
defined. First we applied an unsupervised approach that failed to dis-
criminate any consistent subgroup of patients; in particular, based on a
principal component analysis (PCA), cases with different clinical out-
come were quite mixed up. Similarly, by unsupervised hierarchical
clustering we could not identify major clinical-biological meaningful
groups (data not shown). We then compared, by supervised analysis
(two-tailed T-test, p < 0.05; fold change> 2 and false discovery rate
according to Benjamini-Hockeberg), cases who obtained (N = 14) or
not (N = 12) a CR and we identified 309 genes differentially expressed
in the two groups (Fig. 3A; Supplementary Table 1). Among others, we
found several genes known to be associated with a malignant pheno-
type including CXCR4, FOS, IRF2, IRF7, LEF1, LYN, MYD88, NFKBIA,
PBX1, and RHOA.
Based on the expression of such 309 genes, the samples could be
successfully clustered into two groups that reflected the treatment re-
sponse (χ2, p = 0.04; Fig. 3A). Interestingly, when we looked for spe-
cific biological functions, as defined by the GeneOntology, possibly
enriched (i.e. significantly over-represented) in the panel, we found
genes related to signal transduction, cellular macromolecule metabolic
process, regulation of gene expression, apoptosis, regulation of tran-
scription, intracellular signalling cascade, protein kinase cascade, im-
mune response, RHO protein signal transduction and IKB kinase/
Fig. 1. Trial profile.
Table 1
Baseline characteristics (N = 66).









De novo 28 (42)
Secondary, n 38 (58)
After MDS 29




Median, range 60 (20–95)
20–30 19 (29)
31–50 11 (17)
> 50 36 (54)
Median haemoglobin level, g/dL (range) 9.1 (5.6–14.6)
Median platelet count, × 109/L (range) 31 (3–339)
Median WBC count, × 109/L (range) 3.42 (0.4–49.7)
Cytogenetic risk groupa, n
Not evaluable 4 (6)
Intermediate Karyotype 37 (56)
(30/37 normal karyotype)
Unfavourable Karyotype 25 (38)
(20/25 complex karyotype)
a Defined according to SWOG criteria (Slovack et al., Blood 2000) CMPD, chronic




Event Number of patients (%)
Hematological Toxicity Grade 1–2 Grade 3–4
Trombocytopenia 2 (3%) 47 (71%)
Neutropenia 0 (0%) 40 (61%)
Neutropenic fever 0 (0%) 12 (18%)
Anemia 26 (39%) 20 (30%)
Event Number of patients (%)
Non Hematological Toxicity Grade 1–2 Grade 3–4
Epatobiliary disorders 6 (9%) 2 (3%)
Mucositis 6 (9%) 0 (0%)
Skin disorders 6 (9%) 0 (0%)
Cardiac disorders 3 (5%) 1 (2%)
Sepsis 2 (3%) 0 (0%)
The severity of adverse events was graded on a scale of 1–5 according to the NCI Common
Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0.
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nuclear factor K-B cascade (Fig. 3B; Supplementary Table 2). In addi-
tion, the 309 genes turned out to be significantly enriched in pathways
such as AML with NPM1 mutated, MLL signature 1 and 2, EZH2 targets,
targets of HOXA9 and MEIS1, ATM PCC network, reactome adaptive
immune system, hematopoietic stem cell, myeloid cell development,
bound by PML-RARA fusion that are either related to well characterized
signalling associated to AML or, more generally, to the myeloid system
and the immune response (Fig. 3C; Supplementary Table 3). Further-
more, when pathways relying on specific oncogenes were investigated,
RELA/NFkB, VEGFA, HOXA9, CCND1, MTOR, PDGF and STK33 did
significantly emerge (Fig. 3D; Supplementary Table 4). Of interest, such
processes were indeed biologically sound with the proposed therapy as
lenalidomide is an antiangiogenic and immunomodulatory agent.
We then aimed to identify an easily reproducible assay able to po-
tentially recognize AML patients according to the sensitivity to lenali-
domide and cytarabine before treatment administration. To do this, we
first applied a linear discriminant analysis (based on the 309 genes) to
identify a minimal gene set (MGS) of genes still capable to discriminate
the two groups. We found that 16 genes (ATF3, CHMP6, HCP5, HLA-E,
HOMER3, MGC21881, MID1IP1, MLF2, PAX5, PGLS, PGM1, RHOA,
RTN3, TMEM44, UBE2L3, VAMP8) were sufficient to recapitulate the
entire gene signature in terms of discriminant capability. Indeed, based
on the expression of such 16 genes PCA could discriminate cases ac-
cording to the clinical response (Fig. 4A).
We then investigated the ability of the MGS to predict treatment
response in AML patients. As the relatively limited number of available
samples did not allow to apply the test to an independent validation
panel of cases, we adopted a support vector machine (SVM) approach
with leave-one out method, that ensured to reclassify each sample after
having excluded it from the generation of the classifier. Remarkably,
our assay correctly classified 23/26 AML samples, with very high di-
agnostic accuracy (overall accuracy, 88%, Table 3).
To test the potential clinical impact of the assay, we compared the
OS of patients classified as “predicted responder” or “predicted non-
responder”. We found that the first group behaved significantly better
(mean OS 16.24 months [95% CI 9.64–22.85] vs. 2.36 months [95% CI
1.06–3.67]; p < 0.001; Fig. 4B). Interestingly, the predicted OS curves
generated with our gene set were superimposable to the OS curves of
the patients treated with our combo and split according to response to
therapy (CR vs. no CR).
4. Discussion
Despite the increasing knowledge in molecular pathways involved
in AML development and progression, this has still not led to novel,
successful therapies available in the clinical setting [21]. In this report,
we showed for the first time that low-dose lenalidomide and cytarabine
combination has clinical activity in elderly AML patients, aged 70 years
or more, unfit for standard induction therapy. Remarkably, a specific
molecular signature, independent from the cytogenetic or known mo-
lecular abnormalities already described (including FLT3, NMP1, or
CEBPA mutations), discriminated patients according to treatment re-
sponse.
Recent understanding of leukemia stem cell cycling suggests that
Fig. 2. A–C. Cumulative DFS (A), cumulative OS (B) and OS according to response (C).
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prolonged cytotoxic exposure (14–21 days) could provide a more va-
luable anti-leukemic effect than the typical 3–7 days schedule. This
could be due to a major number of leukemic stem cells able to undergo
cell division in a longer period of time. Low-dose cytarabine has been
widely used in AML treatment. The mechanism of action of low-dose
cytarabine is still debated; however, even if differentiation induction
has been claimed to be important, the majority of clinical studies sup-
ports the view of a preponderant cytotoxic effect on leukemia cells. In
this view, the prolonged use of low-dose cytarabine (15 days) could be
necessary to exert a cytotoxic effect (“debulking”), but it is surely not
enough to explain the 36.3% CR rate of our study. In fact, low-dose
cytarabine is active in AML, but the percentage of responses does not
generally exceed 15–18% and the duration of response is short.
Furthermore, the addition of Gemtuzumab Ozogamicin (GO) to low-
dose cytarabine improved the CR rate, but only to 21% [22].
High-dose lenalidomide (50 mg/day) was able to induce CR/CRi in
30% of untreated, older AML patients [6] and in 16% of relapsed/re-
fractory patients [5]. However, responses were reported almost ex-
clusively in patients with low circulating blast count (< 1000 μl) at
diagnosis, limiting this schedule to a minority of elderly AML patients.
Pollyea and co-workers tested in a phase I–II study the efficacy of
azacitidine followed by sequential lenalidomide at increasing doses in
42 AML patients aged 60 years or older. CR rate was 28%, with 4 pa-
tients being alive and disease-free after a median follow-up for
Fig. 3. A–D. A) Supervised hierarchical clustering based on genes differentially expressed in cases achieving (CR) or not (NR) a complete remission. Such genes were significantly
enriched in cancer/leukemia related pathways (B), relevant biological processes (C) and pathways mastered by known oncoprotein (D).
Fig. 4. A–B. A) Linear discriminant analysis was then
used to reduce the number of genes able to predict
the clinical response up to 16. B) Overall survival of
patients predicted to achieve a CR was significantly
better than in patients predicted for NR (mean OS
24,37 mo vs. 1,36 mo; p < 0.001).
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surviving patients of 88 weeks. However, the Authors did neither de-
scribe a reliable biomarker able to predict response nor a correlation
between methylation and response.
The debulking effect of cytarabine could favourably couple with the
principal mechanism of action of lenalidomide, operating not only in
chronic lymphocytic leukemia, but even interacting with AML cells. In
fact, recent evidence [23] shows a close cross-talk between leukemia
cells and immune elements, with lenalidomide exerting a direct effect
on the leukemic microenvironment, as well as modifying and improving
cell to cell connections. This latter effect of lenalidomide is most
probably favouring the cytotoxic effects of low-dose cytarabine, giving
a preliminary, possible explanation of the promising results arising
from our trial.
In our study, induction-period mortality was 12% (8/66). This is in
line with the induction-period mortality reported from other drug
combinations classified as “low-intensity”, and supports the classifica-
tion of our combined schedule as a “low-intensity” therapy. Moreover,
our results compare favourably with other “low-intensity” therapies
that have been evaluated in older AML including low-dose cytarabine
alone [24], azacitidine [25], tipifarnib [26], decitabine [27,28] and
vorinostat plus GO [29]. Reported CR rates with low-dose cytarabine
alone, azacitidine, tipifarnib, decitabine and vorinostat plus GO were,
respectively, 15%, 8%, 18%, 25% and 19%, with a median OS of 3.6–25
months and induction-period mortality of 10–25%.
In this study, whereas the conventional molecular-genetic analysis
failed to provide significant prognostic information, we were able to
identify, with GEP, few relevant genes differentially expressed in pa-
tients achieving or not a CR. This confirmed that, beside the major
genetic events occurring in AML cells, activation and silencing of
pathways play a significant role. Furthermore, it highlights the intri-
guing possibility that specific treatment schedules, thought not directly
targeted (e.g anti-ABL1, anti PML/RARA), might revert the prognostic
impact of certain genotypes. Actually, we found that the 309 differen-
tially expressed genes were representative of known pathways aber-
rantly regulated in malignant cells. Notably, some of them are known
targets of lenalidomide, including VEGFA and more generally angio-
genesis, the immune response and the NFkB pathway. Based on these
findings, we also tried to evaluate whether targeted GEP might be re-
garded as a useful pre-treatment assessment to identify patients more
likely to achieve a CR and a prolonged survival. We identified 16 genes
that appeared to be promising in this sense. In fact, based on their
expression patterns, we could clearly separate patients who achieved or
not CR. Certainly, independent validation in future studies with lena-
lidomide and cytarabine are warranted.
In conclusion, our data support, for the first time, the prospective
use of a GEP-driven therapy in a cohort of hard-to-treat AML patients,
unfit for standard therapy, with an extremely poor prognosis. In the age
of massive genome surveys, and after the completion of the AML-se-
quencing project which demonstrated the genomic complexity of AML
[30], this is a step forward to an easier and highly active GEP-driven
therapeutic strategy.
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